Iron isomaltoside and ferric carboxymaltose on hypophosphatemic effects in a controlled trial
Results of a study comparing the incidence of hypophosphatemia after high dose IV iron substitution have been presented at the 60th annual meeting of the American Society of Hematology. The HOMe aFers trial recruited women with gynaecological bleeding and subsequent iron deficiency. All subjects were given high dose intravenous iron, randomised between iron isomaltoside and ferric carboxymaltose to correct their iron deficiency. It has been reported[1] that ferric carboxymaltose has a propensity to induce hypophosphatemia. This independent study was conducted…
You might be interested in
